Wells Fargo & Company Icosavax, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$5.95 - $15.79 $9,990 - $26,511	1,679 Added 24.45%	8,547 $134,000
Q3 2023 Nov 13, 2023	SELL	$7.22 - $10.05 $25,797 - $35,908	-3,573 Reduced 34.22%	6,868 $53,000
Q2 2023 Aug 15, 2023	BUY	$4.89 - $10.57 $31,819 - $68,778	6,507 Added 165.4%	10,441 $103,000
Q1 2023 May 12, 2023	BUY	$5.62 - $11.51 $22,109 - $45,280	3,934 New	3,934 $22,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $9.21 $559 - $1,667	-181 Reduced 82.65%	38 $0

Q2 2022 Aug 12, 2022	SELL	$5.7 - $10.33 $38,891 - $70,481	-6,823 Reduced 96.89%	219 $1,000
Q1 2022 May 16, 2022	SELL	$4.41 - $22.5 $9,666 - $49,320	-2,192 Reduced 23.74%	7,042 $50,000
Q4 2021 Feb 14, 2022	BUY	$21.07 - $34.98 $193,127 - $320,626	9,166 Added 13479.41%	9,234 $211,000
Q3 2021 Nov 15, 2021	BUY	$24.85 - $40.25 $1,689 - $2,737	68 New	68 $2,000

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.